Company intelligence / Profile preview
Mirum Pharmaceuticals, Inc.
Foster City, California, United Statesmirumpharma.com ↗
- Ownership
- Public · MIRM
- Employees
- ~311
- Development stage
- Commercial
01
Overview
Mirum has three FDA-approved medications: LIVMARLI (maralixibat) for cholestatic pruritus in ALGS and PFIC patients, CHOLBAM (cholic acid) for bile acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis. The company also has several late-stage pipeline candidates in development.
- Therapeutic areas
- GastroenterologyRare DiseasesNeurologyMetabolic Disorders
- Modalities
- Small moleculesGene therapyIBAT inhibitors
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Vivet Therapeutics
04
Financials
- Market cap
- $6.1B
- Total revenue
- $521.3M
- Enterprise value
- $6.4B
Beyond the preview
Go deeper on Mirum Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mirum Pharmaceuticals, Inc..